EUVIMEDEUVIMED entdecken
Crossref

Association Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality

Zusammenhang zwischen der Gabe systemischer antitumoraler Therapie nahe dem Lebensende und der Nutzung von Gesundheitsversorgung und Hospiz bei älteren Erwachsenen: SEER-Medicare-Analyse zur Qualität der Versorgung am Lebensende

Maureen E Canavan iD, Lee Cheng, Jenny Jing Xiang iD, John Kent Lin iD, David Hui iD, Hui Zhao iD, Nico Nortje iD, Ravin Ratan iD, Nathan Cherny iD, Trinh Pham iD, Sharon H Giordano iD, Jiangong Niu und 1 weitere

Journal of Clinical Oncology · 2025-11 · 43 (31) · 3391-3402

DOI: 10.1200/jco-25-00530 ↗

Auf einen Blick

Bei 315.089 älteren Krebspatient:innen war eine systemische antitumorale Therapie in den letzten 30 Tagen vor dem Tod mit mehr Versorgung im Akutbereich und weniger Hospiznutzung verbunden.

Fragestellung

Wie ist die Gabe systemischer antitumoraler Therapie am Lebensende mit der Nutzung von Gesundheitsversorgung und Hospiz in den letzten 30 Tagen vor dem Tod assoziiert?

Methode

SEER-Medicare-Analyse mit multivariablem Regressionsmodell bei Patient:innen ab 66 Jahren mit mehreren Tumorarten; Diagnosen 2005 bis 2019, Todesfälle 2015 bis 2020.

Ergebnisse

23.970 von 315.089 Begünstigten (7,6 %) erhielten SACT innerhalb von 30 Tagen vor dem Tod. Gegenüber keiner SACT: mehr ED-Nutzung (OR 3,05; 95 %-KI 2,95–3,15), Hospitalisierung (OR 2,64; 95 %-KI 2,56–2,72), ICU (OR 1,78; 95 %-KI 1,72–1,83), Krankenhaussterben (OR 2,02; 95 %-KI 1,96–2,08) und weniger Hospiznutzung (OR 0,51; 95 %-KI 0,50–0,53).

Schlussfolgerung der Autor:innen

Alle SACT-Subtypen waren mit Markern einer schlechteren Versorgungsqualität am Lebensende assoziiert. Die Daten können Entscheidungen für aktuelle Versorgungsleitlinien und Maßnahmen zur Reduktion von Überversorgung informieren.

Kernaussagen

  • SACT in den letzten 30 Tagen vor dem Tod: 7,6 %
  • Mehr ED-Nutzung, Hospitalisierung, ICU und Krankenhaussterben
  • Weniger Hospiznutzung unter SACT als ohne SACT

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, 2025-11. Verfasst von Maureen E Canavan und 12 weiteren Autor:innen. Beteiligte Einrichtung: Yale School of Medicine, New Haven, CT. Hauptthemen laut MEDLINE: Terminal Care, Hospice Care, Neoplasms, Patient Acceptance of Health Care. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 54 Literaturangaben.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Use of cytotoxic chemotherapy at end-of-life (EOL) is associated with adverse quality of life, increased health care utilization, and lower hospice rates. Although EOL cytotoxic chemotherapy use has declined in recent years, EOL novel (immunotherapy and targeted therapy) use has increased. The association between use of novel therapies at EOL and health care utilization has not been widely studied. METHODS We identified patients within SEER-Medicare who had part D coverage (excluding those with Medicare Advantage) age 66 years and older, and breast, colorectal, lung, prostate, bladder, cervical, kidney, liver, ovarian, pancreatic, melanoma, or uterine cancer. Patients were diagnosed between 2005 and 2019 and died between 2015 and 2020. We analyzed associations between EOL systemic anticancer therapy (SACT) use (overall and by subtype), and health care utilization in the last 30 days of life (emergency department [ED], hospitalization, intensive care unit [ICU], and inpatient death), and hospice with multivariable regression, controlling for sociodemographic and cancer covariates. RESULTS Of 315,089 beneficiaries, 23,970 (7.6%) received SACT within 30 days of death. The breakdown by type was cytotoxic therapy 50.6%, immunotherapy 20.8%, targeted therapy 18%, and combination therapies 10.6%. After adjusting for covariates, any SACT use at EOL was associated with higher ED use (odds ratio [OR], 3.05 [95% CI, 2.95 to 3.15]), hospital admissions (OR, 2.64 [95% CI, 2.56 to 2.72]), ICU admission (OR, 1.78 [95% CI, 1.72 to 1.83]), hospital death (OR, 2.02 [95% CI, 1.96 to 2.08]), and lower hospice use (OR, 0.51 [95% CI, 0.50 to 0.53]) compared with no SACT. All subtypes of SACT were individually associated with higher health care utilization and lower hospice use ( P < .001). CONCLUSION All subtypes of SACT use were associated with markers of worse-quality EOL care. These data can inform decisions for current care guidelines and efforts to reduce overutilization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Terminal CareHospice CareNeoplasmsPatient Acceptance of Health CareAntineoplastic AgentsQuality of Health CareHumansAgedUnited StatesFemaleMaleSEER ProgramMedicareAged, 80 and overQuality of Life

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Yale School of Medicine, New Haven, CT.
  • MD Anderson Cancer Center, Houston, TX.
  • Department of Medical Oncology, Shaare Zedek Medical Center, Jerusalem, Israel.
  • Yale New Haven Hospital, New Haven, CT.

ORCID-Profile: Maureen E Canavan, Jenny Jing Xiang, John Kent Lin, David Hui, Hui Zhao, Nico Nortje, Ravin Ratan, Nathan Cherny, Trinh Pham, Sharon H Giordano, Kerin B Adelson

Zitieren

APA

Canavan, M. E., Cheng, L., Xiang, J. J., Lin, J. K., Hui, D., Zhao, H., Nortje, N., Ratan, R., Cherny, N., Pham, T., Giordano, S. H., Niu, J., & Adelson, K. B. (2025). Association Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality. Journal of Clinical Oncology, 43(31), 3391-3402. https://doi.org/10.1200/jco-25-00530

Vancouver

Canavan ME, Cheng L, Xiang JJ, Lin JK, Hui D, Zhao H, et al. Association Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality. Journal of Clinical Oncology. 2025;43(31):3391-3402. doi:10.1200/jco-25-00530

BibTeX
@article{Canavan2025,
  author = {Canavan, Maureen E and Cheng, Lee and Xiang, Jenny Jing and Lin, John Kent and Hui, David and Zhao, Hui and Nortje, Nico and Ratan, Ravin and Cherny, Nathan and Pham, Trinh and Giordano, Sharon H and Niu, Jiangong and Adelson, Kerin B},
  title = {Association Between Systemic Anticancer Therapy Administration Near the End of Life With Health Care and Hospice Utilization in Older Adults: A SEER Medicare Analysis of End-of-Life Care Quality},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {31},
  pages = {3391--3402},
  doi = {10.1200/jco-25-00530}
}
Kostenlos starten →